HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
IPO Year: 2015
Exchange: NASDAQ
Website: htgmolecular.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2022 | $5.00 → $8.00 | Hold → Buy | Craig-Hallum |
Craig-Hallum upgraded HTG Molecular Diagnostics from Hold to Buy and set a new price target of $8.00 from $5.00 previously
SVB Leerink reiterated coverage of HTG Molecular Diagnostics with a rating of Outperform and set a new price target of $10.00 from $15.00 previously
HC Wainwright & Co. reiterated coverage of HTG Molecular Diagnostics with a rating of Buy and set a new price target of $9.00 from $11.00 previously
HC Wainwright & Co. reiterated coverage of HTG Molecular Diagnostics with a rating of Buy and set a new price target of $11.00 from $15.00 previously
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
3 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treat
TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostically across therapy areas. At the center of this approach is HTG's proprietary RNA profiling technologies, functionally married with an adva
TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG's proprietary RNA profiling technologies, functionally married with advanced medicinal chemistry using a novel artificial intelligence ("AI")-driven platform. This unique drug can
TUCSON, Ariz., April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today provided an update on partnering discussions for its drug discovery business unit. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG's proprietary RNA profiling technologies, functionally married with advanced medicinal chemistry using a novel AI-based platform. This unique drug candidate optimization platform is expected to allow for more biolo
TUCSON, Ariz., April 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced the achievement of three significant drug discovery business milestones in the first quarter of 2023. As reported in January 2023, HTG filed a patent application on December 28, 2022, which included claims directed toward specific compounds, pharmaceutical compositions and methods of treating or preventing disease by administration of the compounds for its first target and indication. These compounds were designed by the company's advanced machine-learning medicinal chemistry platform using a target-first a
TUCSON, Ariz., Jan. 09, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today provided an update on the progress of its drug discovery business unit, including the filing of a patent application directed towards its first therapeutics target, and announced that its management team will be hosting in-person meetings at the LifeSci Partners 2023 Corporate Access Event from January 9-11, 2023 in San Francisco, CA. HTG Therapeutics, the company's drug discovery business unit, has been actively using its transcriptome
Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. Total revenue for the full year 2022 is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of our total revenue. Cash and cash
TUCSON, Ariz., Dec. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, provides here a summary of its second HTG Therapeutics key opinion leader (KOL) webinar: "The Role of RNA Profiling in Drug Discovery and Analysis," hosted on Tuesday, December 13, 2022. In this latest webinar, Dr. Robert Spitale of the University of California, Irvine, delved into the many potential roles for RNA profiling in drug discovery and development and how it can be leveraged to improve the selection of lead compounds. Dr. Spitale d
TUCSON, Ariz., Dec. 23, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced the closing of its previously announced public offering of an aggregate of 1,290,322 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share (or pre-funded warrant) and accompanying warrants. The Series A-1 warrants have a
TUCSON, Ariz., Dec. 21, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced the pricing of a public offering of an aggregate of 1,290,322 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share (or pre-funded warrant) and accompanying warrants. The Series A-1 warrants will have an exercise price o
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
10-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. Total revenue for the full year 2022 is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of our total revenue. Cash and cash
TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June 30, 2022. Throughout the quarter ended June 30, 2022, the Company's technology and strategic development efforts were highlighted in a number of customer and KOL presentations and publications including, but not limited to, the following: A webinar titled "Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research" fe
TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended June 30, 2022 after the market close on Thursday, August 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows: Conference Call & Webcast Details Date:Thursday, August 11Time:4:30pm ETToll Free:1-800-954-0602 International:1-212-231-2936 Conference ID:2
TUCSON, Ariz., May 12, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended March 31, 2022. Recent Business Highlights Released a proof-of-approach white paper, demonstrating the utility of HTG's proprietary profiling technologies as a key component of its novel drug discovery and design platform. Expanded the HTG Therapeutics business unit leadership team with the addition of Christina M. Carruthers, Ph.D., as Vice President of Target Strategy and Early Developmen
TUCSON, Ariz., May 05, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended March 31, 2022 after the market close on Thursday, May 12, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows: Conference Call & Webcast Details Date:Thursday, May 12Time:4:30pm ETToll Free:1-855-327-6837 International:1-631-891-4304Conference ID:10019008
TUCSON, Ariz., March 29, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its financial results for the year ended December 31, 2021. Recent Business Highlights HTG Transcriptome Panel ("HTP") revenue continued to increase in the fourth quarter of 2021, ending the year as the top selling assay at approximately 16% of total revenue, just 5 months after commercial sales availability. Announced the expansion of its therapeutics team with the addition of several highly experienced professionals, led by Stephen Barat, Ph.D., a drug dev
TUCSON, Ariz., March 22, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the year ended December 31, 2021 after the market close on Tuesday, March 29, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows: Conference Call & Webcast Details Date:Tuesday, March 29Time:4:30pm ETToll Free:1-855-327-6837International:1-631-891-4304Conference ID:10018
Preliminary full year 2021 unaudited revenue of $8.9 million Cash, cash equivalents and short-term marketable securities of $21.9 million as of December 31, 2021 TUCSON, Ariz., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced certain preliminary, unaudited financial results for the year ended December 31, 2021. Total revenue for the full year 2021 is expected to be approximately $8.9 million, including approximately $1.4 million of HTG Transcriptome Panel (HTP) revenue. Cash, cash equivalents and short-term marketable securities are approximately $21.9 million as
TUCSON, Ariz., Nov. 10, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its financial results for the quarter ended September 30, 2021. Recent Business Highlights Total revenue for the quarter ended September 30, 2021 increased by approximately 42% when compared to the same period in 2020. HTG Transcriptome Panel revenue increased in the third quarter and accounted for 27% and 18% of consumables product revenue for the three and nine months ended September 30, 2021, respectively.Continued collaboration with participants in the Ea
TUCSON, Ariz., Nov. 02, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a life science company advancing precision medicine through its transcriptome-wide technology, today announced that it will report its financial results for the third quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 pm ET. Conference Call & Webcast DetailsDate:Wednesday, November 10Time: 4:30 pm ETToll Free:877-407-0789 International:201-689-8562Conference ID:13723995Webcast:https://78449.themediaframe.com/dataconf/productusers/vvd
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13D/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13D/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13D - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)